Our transgenic liver cancer models induced by TAZS89A plus BRAFV600E and TAZS89A plus PI3KE545K are expected to be useful for various studies, such as investigation of molecular pathogenesis of liver cancers, cross-talks between YAP/TAZ and EGFR/HER2 signaling pathways, and etc. As well, the models can be effective applied to evaluate efficacies of molecular target therapies for HCC and CC. This evidence concerns the gene ERBB2 and hepatocellular carcinoma.